Cheap AI shakes markets while Europe beats US on vaccines

Here is the part that should make every AI executive a little uncomfortable: a Chinese lab just built a model competitive with the best offerings from OpenAI and Anthropic, and is charging roughly 83% less to use it.

DeepSeek-V4 is the latest release from the Hangzhou-based research outfit that has become something of a recurring nightmare for Silicon Valley's pricing assumptions. According to early benchmarks, V4 lands in near-state-of-the-art territory across reasoning, coding, and language tasks — putting it in the same conversation as GPT-5 and Claude Opus 4.7 — while undercutting both on API costs by a factor of six.

To put that in dollars-and-sense terms: tasks that cost a dollar on a top-tier Western model might run around 16 or 17 cents on DeepSeek-V4. For companies running inference at scale, that is not a rounding error. That is a budget line item that rewrites itself.

What makes this particularly striking is the trajectory. DeepSeek burst onto the scene earlier this year with R1, a reasoning model that rattled markets and briefly wiped billions off Nvidia's market cap when developers realized you did not necessarily need the most expensive hardware to get elite results. V4 suggests that was not a fluke — it was a preview of a sustained cost-efficiency strategy that Western labs have struggled to match.

The implications run deeper than just sticker price. The AI industry has operated on an implicit assumption that frontier intelligence is expensive to produce and expensive to access. DeepSeek keeps stress-testing that assumption, and it keeps failing. If a model this capable can be offered at these price points, it raises real questions about whether the capital-intensive approach favored by OpenAI, Google, and Anthropic is a durable competitive moat — or just an expensive habit.

For enterprise buyers, V4 creates genuine optionality that did not exist six months ago. Switching costs in AI are relatively low compared to traditional software, which means procurement teams now have a credible alternative to wave at their current vendors during contract negotiations. That alone shifts leverage in the market.

The geopolitical dimension is impossible to ignore, either. As the US government tightens chip export controls aimed at slowing Chinese AI development, DeepSeek's continued progress suggests those controls are either arriving too late, being worked around through efficient architecture design, or both. The policy and the technical reality are not quite syncing up.

DeepSeek-V4 is not a perfect product. Questions around data privacy, censorship on politically sensitive topics, and reliability for enterprise compliance use cases remain legitimate concerns that Western alternatives have used to maintain their footholds. But on raw capability per dollar, the gap between East and West just got meaningfully smaller — and that is a sentence the AI industry will need to keep reckoning with.

A vaccine invented in the United States, funded in part by American taxpayer dollars, just became available to Europeans first — because US regulators, under political pressure, will not review it.

The European Commission this week authorized Moderna's mCOMBRIAX, a single combination shot that protects against both influenza and COVID-19. It is a genuine first: no country had previously approved a combo vaccine targeting both respiratory viruses in one dose. The decision follows a favorable scientific review by a key European Medicines Agency committee in February and opens the door to distribution across all 27 EU member states, plus Iceland, Liechtenstein, and Norway — potentially in time for the next flu season.

The clinical data behind the approval is solid. A Phase III trial of roughly 4,000 adults showed mCOMBRIAX produced statistically stronger immune responses against common flu strains and SARS-CoV-2 than existing standard and high-dose flu vaccines used as comparators. Safety and adverse event profiles were not a concern.

The convenience case almost sells itself. Flu and COVID shots are already recommended on overlapping schedules for high-risk adults. Combining them reduces the number of clinic visits, cuts administration costs for healthcare systems, and removes a friction point that causes people to skip one or both shots. Public health officials have been chasing that kind of behavioral nudge for years.

Now for the part that stings. Moderna originally submitted mCOMBRIAX for FDA approval, then withdrew the application in May 2025, citing the need for additional data on the investigational flu component. That kind of resubmission process is not unusual. What came next was. The FDA — under a decision attributed to political appointee Vinay Prasad, made over the objections of the agency's own scientific staff — refused to even review Moderna's separate application for the standalone flu vaccine that underpins the combo shot. No review, no path forward.

Meanwhile, the Trump administration's Department of Health and Human Services, led by Robert F. Kennedy Jr., has canceled hundreds of millions of dollars in federal grants that had been funding Moderna's mRNA vaccine pipeline. Kennedy has been openly skeptical of mRNA technology despite its demonstrated safety record and its central role in the COVID-19 vaccine rollout that saved millions of lives.

The result is a quietly extraordinary situation: a product developed with significant American scientific and financial investment is now a commercial reality in Europe while remaining in regulatory limbo at home for reasons that have more to do with ideology than evidence.

For Moderna investors, the European authorization at least opens a meaningful revenue path. For American adults who would prefer a single annual shot over two, the wait continues indefinitely — not because the science is unclear, but because the politics are not.